Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes

Shestakova, Marina Vladimirovna; Владимировна, Шестакова Марина; Antciferov, Michail; Борисович, Анциферов Михаил; Mayorov, Alexander Yur'evich; Юрьевич, Майоров Александр; Ruyatkina, L. A.; Александровна, Руяткина Людмила; Суплотова, Л. А.; Александровна, Суплотова Людмила; Догадин, С. А.; Анатольевич, Догадкин Сергей; Lebedev, N. B.; Борисович, Лебедев Николай; Alekseeva, Yana G.; Геннадиевна, Алексеева Яна

doi:10.14341/dm7694

Cited by 3 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sixty-five unique studies and 13 companion reports were included (Appendix File 1); 27 and 37 studies were included in the basal insulin class and insulin class/origin/frequency analyses, respectively. Six [37][38][39][40][41][42] non-English studies and two protocols 43,44 were included. Authors of 89 studies were emailed and responses were received for 18 studies; one 45 provided additional data for the analysis.…”

Section: Literature Searchmentioning

confidence: 99%

Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

BACKGROUND: Increasing availability of competing biosimilar alternatives makes it challenging to make treatment decisions. The purpose of this review is to evaluate the comparative efficacy and safety of ultra-long-/ long-/intermediate-acting insulin products and biosimilar insulin compared to human/animal insulin in adults with type 1 diabetes mellitus (T1DM). METHODS: MEDLINE, EMBASE, CENTRAL, and grey literature were searched from inception to March 27, 2019. Randomized controlled trials (RCTs), quasiexperimental studies, and cohort studies of adults with T1DM receiving ultra-long-/long-/intermediate-acting insulin, compared to each other, as well as biosimilar insulin compared to human/animal insulin were eligible for inclusion. Two reviewers independently screened studies, abstracted data, and appraised risk-of-bias. Pairwise meta-analyses and network meta-analyses (NMA) were conducted. Summary effect measures were mean differences (MD) and odds ratios (OR). RESULTS: We included 65 unique studies examining 14,200 patients with T1DM. Both ultra-long-acting and long-acting insulin were superior to intermediate-acting insulin in reducing A1c, FPG, weight gain, and the incidence of major, serious, or nocturnal hypoglycemia. For fasting blood glucose, long-acting once a day (od) was superior to long-acting twice a day (bid) (MD -0.44, 95% CI: -0.81 to -0.06) and ultra-long-acting od was superior to long-acting bid (MD -0.73, 95% CI -1.36 to -0.11). For weight change, long-acting od was inferior to long-acting bid (MD 0.58, 95% CI: 0.05 to 1.10) and long-acting bid was superior to long-action biosimilar od (MD -0.90, 95% CI: -1.67 to -0.12). CONCLUSIONS: Our results can be used to tailor insulin treatment according to the desired results of patients and clinicians and inform strategies to establish a competitive clinical market, address systemic barriers, expand the pool of potential suppliers, and favor insulin price reduction.

show abstract

Section: Literature Searchmentioning

confidence: 99%

Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus

Hemmingsen

Metzendorf

Richter

2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

Дьяков¹,

Зырянов

2021

GCP

View full text Add to dashboard Cite

Effective control of Diabetes Mellitus (DM) is an actual task from clinical and economic points of view. The second generation insulin analogs increase level of DM compensation without hypoglycemia. The economic aspects of their usage have been evaluated early, but it is still actual due to changes in prices and new data about clinical efficacy were published.Materials and methods: Clinical-economic comparison of insulin glargine 300 U/ml (iGla 300), insulin degludec (iDeg) and insulin degludec/ insulin aspart (iDegAsp) in the Russian conditions has been performed in naïve patients’ group as well as in the group of patients with previous insulintherapy. Number of patients with HbA1c <7 % was chosen as efficacy criterion. Direct and indirect costs (medications, treatment of CV-complications, GDP loses etc.) were indicated and calculated based on the constructed model.Results: iGla 300 can give an economy till 20 % for medication cost and till 10 % for direct medical expenditures in compare with iDeg in DM Type 1. For both patients’ groups iGla 300 can save 10-23 % of sources in compare with iGed and iDegAsp in DM Type 2. In DM2T iGla 300 had more efficacy and less cost in compare with iDeg in elderly patients with renal insufficiency.Conclusion: An effective control of DM with modern insulins is profitable from government position of payment due to decreasing expenditures for complications treatment.

show abstract

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes

Cited by 3 publications

References 37 publications

Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base

Contact Info

Product

Resources

About